BioSpace News Archive

Juniper Networks, a leader in secure, AI-driven networks, announced that Divi’s Laboratories, one of the largest active pharmaceutical ingredients companies globally, has selected Juniper to deliver highly available, ultra-reliable networking solutions across its manufacturing operations, the largest API manufacturing facilities in the world.

Pharming Group N.V. announces that the first patient has been enrolled in its Phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome.

Further strong organic growth was reported for the year and quarter. Efforts to build an international marketing and sales organization are starting to pay off.

Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced the closing of an oversubscribed $135 million Series B financing.

Verona Pharma plc announces that it will report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, March 7, 2023 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Royal Philips, a global leader in health technology, published its Annual Report 2022.

Apax’s investment, together with the management and current shareholders of the company, will allow Porsolt to further grow and implement its strategy to become a comprehensive preclinical service company, addressing the varying therapeutical areas of the global Pharma, Biotech, and research communities.

BioInvent International AB invites investors and analysts to a presentation of the Year-end report 2022 at 2:00 pm CET on February 22.

Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on Monday, February 27, 2023.

Insulet Corporation announced the presentation of new real-world evidence related to the Omnipod® 5 Automated Insulin Delivery System at the 16th International Conference on Advanced Technologies & Treatments for Diabetes taking place February 22 – 25, 2023 in Berlin, Germany, and online.